International Workshop on HIV & Women 2019

Slideset

HIV

Clinical case: Researcher perspective - Tendani Gaolathe, MD

Slideset

HIV

INSTI exposure and neural tube defects – data from antiretroviral pregnancy registry - Jessica Albano, PhD, MPH

Slideset

HIV

Clinical case: Policy implications - Meg Doherty, MD, PhD

Slideset

HIV

Congenital anomalies in infants of Canadian women exposed to antiretrovirals including dolutegravir - Deborah Money, MD

Slideset

HIV

Clinical development strategy to inform dosing of antiretroviral drugs in women: dolutegravir as a case study - Kimberly Adkison, PhD

Slideset

HIV

Emerging drug delivery systems for treatment and prevention of HIV- Kimberly Scarsi, PharmD, MS, FCCP

Slideset

HIV

HIV risk and characteristics of women seeking PrEP in a US demonstration project - Jill Blumenthal, MD

Slideset

HIV

Innovative intervention for pregnant and breastfeeding adolescent mothers to enhance viral suppression in Homa Bay County, Kenya - Elizabeth Okoth (presented by N. Rakhmanina), MPH

Slideset

HIV

High PrEP uptake among HIV-exposed women with pregnancy plans in South Africa - Lynn Matthews, MD

Slideset

HIV

Non-Vaccine Oncogenic HPV Persistence Among HPV-Vaccinated Women Living with HIV - Elisabeth McClymont

Slideset

HIV

Cardiac Muscle Health Among Women Aging with HIV - Markella Zanni, MD

Slideset

HIV

Dolutegravir pharmacokinetics during pregnancy and postpartum - Angela Colbers, PhD

Slideset

HIV

Vaginal microbiome and associations with tenofovir diphosphate and lamivudine triphosphate in cervical tissues of Ugandan women - Melanie Nicol, PharmD, PhD

Slideset

HIV

HIV Cure: Where have we been, where are we going? - Daniel Kuritzkes, MD

Slideset

HIV

International Workshop on HIV & Women 2019

Clinical case: Researcher perspective - Tendani Gaolathe, MD

INSTI exposure and neural tube defects – data from antiretroviral pregnancy registry - Jessica Albano, PhD, MPH

Clinical case: Policy implications - Meg Doherty, MD, PhD

Congenital anomalies in infants of Canadian women exposed to antiretrovirals including dolutegravir - Deborah Money, MD

Clinical development strategy to inform dosing of antiretroviral drugs in women: dolutegravir as a case study - Kimberly Adkison, PhD

Emerging drug delivery systems for treatment and prevention of HIV- Kimberly Scarsi, PharmD, MS, FCCP

HIV risk and characteristics of women seeking PrEP in a US demonstration project - Jill Blumenthal, MD

Innovative intervention for pregnant and breastfeeding adolescent mothers to enhance viral suppression in Homa Bay County, Kenya - Elizabeth Okoth (presented by N. Rakhmanina), MPH

High PrEP uptake among HIV-exposed women with pregnancy plans in South Africa - Lynn Matthews, MD

Non-Vaccine Oncogenic HPV Persistence Among HPV-Vaccinated Women Living with HIV - Elisabeth McClymont

Cardiac Muscle Health Among Women Aging with HIV - Markella Zanni, MD

Dolutegravir pharmacokinetics during pregnancy and postpartum - Angela Colbers, PhD

Vaginal microbiome and associations with tenofovir diphosphate and lamivudine triphosphate in cervical tissues of Ugandan women - Melanie Nicol, PharmD, PhD

HIV Cure: Where have we been, where are we going? - Daniel Kuritzkes, MD

Invited lecture: Focus on women - Jintanat Ananworanich, MD, PhD